Sales breakdown 2004 - Solvay

More documents

Recommendations

Info

Other agreements Research and Development process for pharmaceuticals products Global Annual Report Solvay 2004 20 With Quintiles (USA) to accelerate early clinical trials In October 2004, Solvay Pharmaceuticals concluded a novel agreement with Quintiles that will effectively double Solvay Pharmaceuticals’ capacity to process its early clinical projects. Through this agreement, Quintiles and its subsidiary PharmaBio Development, which specializes in clinical development, confirm the interest that third parties are showing in the R&D portfolio of Solvay, which is considered a preferred partner in the pharmaceuticals industry. Acquisition of Italmex (Mexico), now the Group's second pharmaceuticals base in Latin America after Brazil. In late 2004 Solvay Pharmaceuticals acquired the Mexican pharmaceuticals company Italmex. This acquisition reflects Solvay Pharmaceuticals’ intention to expand in Latin America, and particularly Mexico, which represents 40% of all pharmaceuticals sales in Latin America. This acquisition is part of the Group's growth strategy in the region and follows the acquisition, in 2000, of Brazilian company Sintofarma (now Solvay Farma). Each new medicine follows the same precisely defined five-stage development path right across the pharmaceuticals industry: – Pre-clinical research: identification of active molecules – Clinical Development: • Phase I: trials on limited, voluntary populations, aimed primarily at measuring safety and tolerance, with an initial approach to dosages • Phase II: testing the effectiveness of the compound, measuring benefits against potential risks, and more precise defining administration dosages • Phase III: large-scale trials on patients, principally in order to meet the requirements of the health authorities. – Registration for commercial use: • Phase IV: additional trials aimed at fine-tuning the use of the medicine in practice (phase IV trials can be conducted at the marketing stage). R&D expenditure 2004 EUR 294 million 17% of pharmaceutical sales Pharmaceuticals research The Group again intensified its pharmaceuticals research and development efforts in 2004, with expenditure rising by 4% from EUR 284 million to EUR 294 million (71% of total Group research). The Group now has a very high number of compounds (around 30) at the clinical testing stage. 19% Cardiology 19% Gastroenterology By therapeutic field 36% Mental health 26% Women's and men's health
Pharmaceuticals Sector Pharmaceuticals R&D pipeline Therapeutic fields Cardiology Gastroenterology Hormone Mental health Therapy Pre-clinical 316, 322, 327, 328, 321, NASEP, 332 318, 326 329, 330, 331 Clinical Development 2 1 1 2 Phase I = 6 319: for obesity 317 Combined estrogen 314: for psychosis tedisamil (oral): for irritable and progestogen gel MARINOL ® : new aerosol for atrial fibrillation bowel syndrome (E+P gel): for post-menopause hormone treatment Clinical Development 2 2 2 Phase II = 6 306: for hypertension 324: for anal fissures 310: for psychosis and congestive 325: for anal incontinence 313: for psychosis heart failure 320: for congestive heart failure and kidney disease 21 Global Annual Report Solvay 2004 Clinical Development 1 3 4 Phase III = 8 tedisamil cetrorelix: for endometriosis 308: for Parkinson’s and (intravenous): INFLUVAC ® TC: concomitant affective pathologies for atrial fibrillation influenza vaccine produced bifeprunox: for psychosis by tissue culture technique MARINOL ® (EU): for anorexia in HIV/ FEMOSTON ® low dose: AIDS patients and chemotherapyfemale hormone induced nausea/vomiting replacement therapy fluvoxamine CR: Single-dose daily treatment for obsessive compulsive disorder and social anxiety Filed / Approved by 2 2 4 3 regulatory authorities TEVETEN ® COMBI: CREON ® (Japan): ESTROGEL ® (USA): female LUVOX ® (Japan): for social anxiety = 11 for hypertension for pancreatic deficiency hormone replacement therapy LUVOX ® (USA): moxonidine COMBI: cilansetron: PRESOMEN ® (D): for obsessive compulsive disorder for hypertension for irritable bowel for vasomotor symptoms DUODOPA ® : for Parkinson’s syndrome and osteoporosis prevention INFLUVAC ® TC (EU): preventive influenza vaccine INVIVAC ® (EU): virosomal preventive influenza vaccine Total = 31 7 5 8 11
Page 1 and 2: Global Annual Report 2004 366 days
Page 3 and 4: 366 days of Innovation Acceleration
Page 5 and 6: Sales by sector [EUR million] Total
Page 7 and 8: Mission, Vision, Values 3 Global An
Page 9 and 10: Chairmen’s message and better to
Page 11 and 12: Board of Directors and Corporate Go
Page 13 and 14: Executive Committee and General Man
Page 15 and 16: Our strategy 11 Global Annual Repor
Page 17 and 18: Our Positions Essentials Apart from
Page 19 and 20: Pharmaceuticals Sector tential thro
Page 21 and 22: Pharmaceuticals Sector Flagship pro
Page 23: Pharmaceuticals Sector with the exc
Page 27 and 28: Chemicals Sector rising market Key
Page 29 and 30: Chemicals Sector The “Electrochem
Page 31 and 32: Chemicals Sector 27 Global Annual R
Page 33 and 34: Plastics Sector io and realigning K
Page 35 and 36: Plastics Sector Vinyls (polyvinyl c
Page 37 and 38: Plastics Sector A number of growth
Page 39 and 40: New Business Development for growth
Page 41 and 42: Human Resources Greater listening a
Page 43 and 44: Human Resources European Works Coun
Page 45 and 46: Sustainable Development and consult
Page 47 and 48: Sustainable Development Strengtheni
Page 49 and 50: Management Report 2004 net income u
Page 51 and 52: SENSITIVITY TO ECONOMIC FACTORS The
Page 53 and 54: Consolidated balance sheet EUR mill
Page 55 and 56: IFRS valuation rules The main accou
Page 57 and 58: - Trade liabilities Trade liabiliti
Page 59 and 60: Information per segment for 2004 is
Page 61 and 62: (6) Other operating gains and losse
Page 63 and 64: The tax charge breaks down as follo
Page 65 and 66: (18) Acquisitions / sale of investm
Page 67 and 68: (22) Consolidation differences (goo
Page 69 and 70: (26) Inventories EUR million, at De
Page 71 and 72: The amounts recorded in the balance
Page 73 and 74: Group policy on insurance Solvay Gr
Page 75 and 76:
) Hedging forecast short /medium-te
Page 77 and 78:
The following amounts relating to J
Page 79 and 80:
List of fully consolidated Group co
Page 81 and 82:
Solvay Interox Ltd, Warrington 100
Page 83 and 84:
List of proportionately consolidate
Page 85 and 86:
SOUTH KOREA Daehan Specialty Chemic
Page 87 and 88:
Income statement of Solvay SA (summ
Page 89 and 90:
Information for shareholders SOLVAY
Page 91 and 92:
Shareholders and investors relation
Page 93:
Solvay SA Rue du Prince Albert, 33
show all

Sales breakdown 2004 - Solvay

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?